| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDCD6 |
| Uniprot No | O75340 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-191aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAAYSYRPGPGAGPGPAAGAALPDQSFLWN VFQRVDKDRSGVISDTELQQALSNGTWTPFNPVTVRSIISMFDRENKAGV NFSEFTGVWKYITDWQNVFRTYDRDNSGMIDKNELKQALSGFGYRLSDQF HDILIRKFDRQGRGQIAFDDFIQGCIVLQRLTDIFRRYDTDQDGWIQVSY EQYLSMVFSIV |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于PDCD6重组蛋白的参考文献示例(非真实文献)：
---
1. **《PDCD6重组蛋白在细胞凋亡中的功能研究》**
Zhang L. et al.
摘要：研究通过重组表达PDCD6蛋白，发现其通过与钙离子依赖性蛋白Alix相互作用，调控caspase级联反应，促进肿瘤细胞凋亡。
2. **《PDCD6重组蛋白的结构与自噬调控机制》**
Chen Y. et al.
摘要：解析PDCD6重组蛋白的晶体结构，揭示其C2结构域在自噬小体形成中的作用，为神经退行性疾病治疗提供靶点依据。
3. **《PDCD6重组蛋白在乳腺癌中的表达及临床意义》**
Wang X. et al.
摘要：通过重组PDCD6蛋白制备抗体，发现其在乳腺癌组织中高表达，且与患者生存率负相关，提示其作为潜在预后标志物。
4. **《重组PDCD6蛋白与TRAIL协同诱导肝癌细胞死亡》**
Liu R. et al.
摘要：实验证明重组PDCD6蛋白可增强TRAIL对肝癌细胞的杀伤作用，机制涉及线粒体膜通透性改变及细胞色素C释放。
---
注：以上文献信息为模拟生成，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
**Background of PDCD6 Recombinant Protein**
PDCD6 (Programmed Cell Death 6), also known as ALG-2 (Apoptosis-Linked Gene 2), is a calcium-binding protein belonging to the penta-EF-hand (PEF) family. It plays a critical role in calcium-dependent signaling pathways regulating apoptosis, membrane trafficking, and endoplasmic reticulum (ER) stress response. PDCD6 interacts with various partners, such as ALIX and Sec31A, to modulate processes like exosome formation, vesicle transport, and cell death execution. Its dysregulation is implicated in cancers, neurodegenerative disorders, and immune diseases.
Recombinant PDCD6 protein is produced via molecular cloning, typically expressed in *E. coli* or mammalian systems, followed by purification to ensure homogeneity and bioactivity. This engineered protein retains functional domains, including EF-hands for calcium binding and motifs for partner protein interactions. Researchers utilize PDCD6 recombinant protein to study its structural dynamics, calcium-dependent conformational changes, and molecular mechanisms in vitro. It also serves as a tool for screening therapeutic agents targeting PDCD6-related pathways or for developing diagnostic biomarkers.
The availability of recombinant PDCD6 has advanced insights into its dual roles in pro-survival and pro-death contexts, highlighting its potential as a therapeutic target. Studies leveraging this protein have clarified its involvement in diseases like hepatocellular carcinoma and Alzheimer’s, where altered PDCD6 expression correlates with pathogenesis. Ongoing research aims to unravel its pleiotropic functions and exploit its regulatory networks for precision medicine applications.
×
